First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that the first patient has been randomised in the phase II study (anaGO) to evaluate efficacy and safety of Kineret® (anakinra) in the treatment of acute gout. The purpose of the study is to evaluate pain relief in people with acute gout who cannot take or have not previously responded to non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine. The anaGO study is a randomised, double-blind, multicentre study being conducted in North America studying two dose levels of anakinra (s.c.) in comparison to